<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02927483</url>
  </required_header>
  <id_info>
    <org_study_id>OPSUN/0116/FS</org_study_id>
    <nct_id>NCT02927483</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Endolex Forte VErsus Diosmin and Hesperidin in Reducing VeNous Insufficiency</brief_title>
  <acronym>EVELINE</acronym>
  <official_title>A Comparative Study to Assess the Efficacy and Safety of Endolex Forte vs Diosmin and Hesperidin in Reducing the symptomatoLogy of Patients With ChronIc VeNous Insufficiency Between Functional Classes CEAP 1-4, During a Period of 6 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SunWave Pharma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Opera Contract Research Organization SRL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SunWave Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is designed as a randomized, multicenter, open label, comparative, 6 months,
      clinical study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, multicentered, open label, comparative study to assess the efficacy and safety
      of Endolex Forte® versus a combination of micronized diosmin (450 mg) and micronized
      hesperidin (50 mg) in reducing the symptomatology of patients diagnosed with Chronic Venous
      Insufficiency which is rated between functional classes CEAP 1-4, during a period of 6
      months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in limb volume determination at day 180 (water displacement method)</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in limb volume determination at day 90 (water displacement method)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-treatment (baseline) in the calf circumference on treatment day 30</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from pre-treatment (baseline) in the calf circumference on treatment day 180</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the subjective symptoms of CVI (tired, heavy legs, sensation of tension in the legs, pain in the legs) measured by Visual Analogue Scales (VAS) at day 90</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the subjective symptoms of CVI (tired, heavy legs, sensation of tension in the legs, pain in the legs) measured by Visual Analogue Scales (VAS) at day 180</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of efficacy by the investigator at day 180</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire on improvement in symptoms at day 180 (CIVIQ-20)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability by the investigator at day 180</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Venous Insufficiency</condition>
  <arm_group>
    <arm_group_label>Endolex Forte®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A combination of diosmin and hesperidin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Endolex Forte®</intervention_name>
    <description>Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.</description>
    <arm_group_label>Endolex Forte®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>A combination of diosmin and hesperidin</intervention_name>
    <description>A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.</description>
    <arm_group_label>A combination of diosmin and hesperidin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients, male or females aged 18 to 75 years old

          -  BMI≤40

          -  Presence of chronic venous insufficiency which is rated between functional classes
             CEAP 1-4

          -  Patients diagnosed with superficial vein thrombophlebitis and have skin reaction by
             redness, swelling, fever and pain symptoms.or patients presenting a painful venous
             symptomatology in the lower limbs for at least 30 days.

          -  Willing and able to give written informed consent prior to participation in the trial

          -  Patients expected to be compliant with the study treatment

        Exclusion Criteria:

          -  Known allergy to the product's ingredients

          -  Pregnancy or breastfeeding

          -  Patient is involved in any other clinical trial

          -  Deep vein thrombosis

          -  Stasis dermatitis

          -  The patient is taking non-steroids anti-inflammatory drugs include oral , topical
             creams or patch form)

          -  Open ulcers or lower extremity amputation

          -  Patient treated by venotonic treatments or vascular protectants or assimilated dietary
             supplements or homeopathic treatments or diuretics within 15 days prior inclusion

          -  Patient presenting permanent oedema,

          -  Patient with a history of lower limbs trauma responsible for sequel pains

          -  NYHA III and IV Heart Failure

          -  Renal Failure

          -  Untreated or uncontrolled Arterial Hypertension

          -  Hepatic Failure

          -  History of a known liver disease such as hepatitis A, hepatitis B, or C.

          -  Malignant neoplasms, from any etiology, or who are receiving any type of anticancer
             treatment, unless when properly treated and with no evidence of recurrence during the
             last five years

          -  Previous history of alcoholism, drug abuse, psychological or emotional problems in the
             last 5 years that can invalidate the Informed Consent Form or restrain participant's
             ability to comply with the requirements of the protocol.

          -  Immobility.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Calin Giurcaneanu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spitalul Universitar de Urgenta Elias, Sectia Dermatologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dionisio Barattini, MD</last_name>
    <phone>+39 335 5437574</phone>
    <email>barattini@operacro.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Serban Rosu, MD</last_name>
    <phone>+40 722 313224</phone>
    <email>rosu@operacro.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation. 2005 May 10;111(18):2398-409. Review.</citation>
    <PMID>15883226</PMID>
  </reference>
  <reference>
    <citation>Olin JW, Beusterien KM, Childs MB, Seavey C, McHugh L, Griffiths RI. Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Vasc Med. 1999;4(1):1-7.</citation>
    <PMID>10355863</PMID>
  </reference>
  <reference>
    <citation>Porter JM, Moneta GL. Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. J Vasc Surg. 1995 Apr;21(4):635-45.</citation>
    <PMID>7707568</PMID>
  </reference>
  <reference>
    <citation>Rabe E, Stücker M, Ottillinger B. Water displacement leg volumetry in clinical studies--a discussion of error sources. BMC Med Res Methodol. 2010 Jan 13;10:5. doi: 10.1186/1471-2288-10-5. Review.</citation>
    <PMID>20070899</PMID>
  </reference>
  <reference>
    <citation>Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg. 2011 Jan;41(1):117-25. doi: 10.1016/j.ejvs.2010.09.025. Epub 2010 Dec 3. Review.</citation>
    <PMID>21126890</PMID>
  </reference>
  <reference>
    <citation>Monograph. Diosmin. Altern Med Rev. 2004 Sep;9(3):308-11. Review.</citation>
    <PMID>15387721</PMID>
  </reference>
  <reference>
    <citation>Sezer A, Usta U, Kocak Z, Yagci MA. The effect of a flavonoid fractions diosmin + hesperidin on radiation-induced acute proctitis in a rat model. J Cancer Res Ther. 2011 Apr-Jun;7(2):152-6. doi: 10.4103/0973-1482.82927.</citation>
    <PMID>21768702</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>October 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2016</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

